Company intelligence / Profile preview

Stuart Pharms

Pasadena, California, United States

Ownership: Private
Development stage: Other

Overview

The company was best known for developing and commercializing the indigestion remedy Mylanta. It remained independent until its acquisition by Johnson & Johnson/Merck in 1991. No current clinical results as the entity is defunct.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Pharma

Partnerships

Merck/Johnson & Johnson partnership post-acquisition

Beyond the preview

Go deeper on Stuart Pharms.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stuart Pharms.